Your patients with early-stage HR+, HER2-, breast cancer - one test for all

The Oncotype DX Breast Recurrence Score test was uniquely designed to help identify which patients with HR+, HER2-, early-stage breast cancer who need chemotherapy. By revealing tumour biology beyond clinical-pathological parameters, it shifts decision-making from assumed to proven chemotherapy benefit for your patients^1-6.

Predictive parameters help guide treatment decisions^1,2,4-7

Predictive markers can inform treatment decisions and avoid extrapolation from prognostic factors. Predictive markers such as ER and HER2 status identify patients responding to hormonal treatment and trastuzumab, respectively⁷. The Recurrence Score result informs whether a tumour is likely to respond to chemotherapy. The NSABP B-20 and SWOG 8814 studies established the predictive value of the Recurrence Score result and the TAILORx and RxPONDER studies further refined the estimates of chemotherapy benefit. These landmark trials showed the majority of patients do not benefit from chemotherapy. Furthermore, these two trials included analysis on age and menopausal status to allow for personalised decision making based on a patient's age and/or menopausal status as well as their Recurrence Score^® result.^1-6

Predictive markers can inform treatment decisions

Prognostic parameters alone cannot guide treatment decisions with precision^2,5,6,11-16

In clinical practice, treatment decisions are often made based on prognostic factors such as tumour size and grade². However, such clinical-pathological parameters are prognostic and have not been demonstrated to predict chemotherapy benefit.^2,5,6,11 Furthermore, several studies have established that clinical-pathological features cannot predict Recurrence Score^®results, such as the below analysis from Germany which shows there is a range of Recurrence Score results across the clinical-pathological features..^2,12-16

b Low clinical risk:
N0, T ≤3 cm and Grade 1
N0, T ≤2 cm and Grade 2
N0, T ≤1 cm and Grade 3
N1, T ≤2 cm and Grade 1
High clinical risk: all other cases

Uncertainty about treatment decisions based on clinical-pathological features alone¹³

A recent study showed that relying on these clinical-pathological factors alone is associated with a high level of uncertainty amongst physicians regarding their treatment decisions. Testing with the Oncotype DX^® assay provided greater confidence to clinicians in their treatment recommendations.¹³

The Oncotype DX Breast Recurrence Score test was uniquely designed to help identify the patients who need chemotherapy^1,4. The TAILORx and RxPONDER studies have added to the evidence base to further refine the chemotherapy benefit by age or menopausal^2,5,6. The data also shows the Recurrence Score result is independent of clinical-pathological features². The Oncotype DX test can be considered for all HR+, HER2-, early-stage breast cancer patients to help guide their chemotherapy treatment decisions.